(MTXX) Matrixx Initiatives Inc. – Aggressive Growth – Zacks Rank Buy

April 16th, 2009

Matrixx Initiatives, Inc. (MTXX) blew away analyst estimates, driven by strong organic sales growth for its fourth consecutive earnings surprise.

Company Description

Matrixx Initiatives, Inc. is a nutrient and drug delivery technology company engaged in the development, manufacture and marketing of delivery systems for bioactive compounds. Gel Tech, LLC, its wholly-owned subsidiary, produces, markets and sells over-the-counter treatments under the Zicam name.

Sales up 26%

In the latest earnings announcement, on Jan 26, Matrixx reported earnings per share of 50 cents. The consensus was just 31 cents making it a 61% and fourth consecutive surprise. Matrixx posted a 7 cent loss in the third-quarter of last year.

A 26% spike in sales was the main driver behind the excellent quarter, specifically the company’s Cold Remedy swabs and new Allergy swabs.

Revisions and Growth

Analysts have upped their estimates over the past 3 months, with just a slight pull back for the current year. The consensus for full-year 2009 is now $1.35, up from $1.27, a 29% growth rate.

Estimates for 2010 are now averaging $1.62, up from $1.55, and represent a year-over-year increase of 20%.

Despite high growth rates, shares are trading at good valuations. The P/E ratio is just 9.1 times earnings and the stock carries a PEG ratio of only 0.7.

Zacks Investment Research
View original at: Zacks.com News Feed

More on this topic (What's this?)
Is the SEC Toast? (Skeptical CPA, 7/16/09)
Trading results 7/14/2009 (Robert Weinstein Trading Blog, 7/14/09)
WHY I HAVE NEVER BOUGHT A DRUG COMPANY (THE PRAGMATIC CAPITALIST, 6/16/09)
Matrixx Initiatives, Inc. Reports Fiscal 2011 Second Quarter Net Sales of $21.3 Million - EPS: $0.57 (Benzinga, 10/25/10)
Read more on Matrixx Initiatives at Wikinvest

Related Posts:

  1. (DLM) Del Monte Foods, Co. – Aggressive Growth – Zacks Rank BuyDel Monte Foods, Co. (DLM) analysts are raising estimates following the most recent earnings report....
  2. (MTXX) Matrix Initiatives, Inc. – Value – Zacks Rank BuyMatrix Initiatives Inc. (MTXX) is cashing in on over-the-counter cough and cold products as revenue...
  3. (GTIV) Gentiva Health, Inc. – Aggressive Growth – Zacks Rank BuyGentiva Health Services, Inc. (GTIV) has continued its streak by announcing its third consecutive earnings...
  4. (PCLN) Priceline.com Inc – Aggressive Growth – Zacks Rank BuyPriceline.com, Inc. (PCLN) just beat Wall Street’s expectations on Feb 18th. Earnings estimates and shares...
  5. (MTXX) Matrixx Initiatives – fourth time in the last four quarters that Matrixx has beat estimatesMatrixx Initiatives, Inc. (MTXX) posted impressive third-quarter results in late January, sending its share price...
  6. (MTXX) Matrixx Initiatives, Inc – Analyst estimates have continued to tick higherMatrixx Initiatives, Inc. (MTXX) is fresh off the heels of another strong quarter, reporting results...


Search Posts by Tag: | | Drug Delivery | Healthcare

RSS Feeds by Tag: Matrixx Initiatives Inc. | MTXX | Drug Delivery | Healthcare |

Other Posts by: | RSS Feed for this author